
VitusCare Raises US$3M Series B — Singapore's Liberty Ridge Capital Backs India's Dialysis Scale-Up
Dialysis care provider VitusCare has raised US$3 million (about ₹30 crore) in a Series B round, reported on 19 November 2026 by Business Standard, ETHealthworld and Entrackr. Singapore's Liberty Ridge Capital is among the investors. We found no standalone press release, so every fact below is attributed to those outlets.
About the author: Jason Lim is a coach with 20+ years of experience who has mentored founders and startups since 2016, helping founders in Singapore, Malaysia, China, Taiwan and Indonesia with sales pitches and presentations (per authorjason.com).
Your next funding conversation is an opportunity. Prepare for it. Jason Lim's Presentation Skills Coaching Program publishes its formats on the page, from a 4-week Beginners' Class to a 12-week Signature class, so you can see the steps and time commitment before you apply. It is aimed at getting your pitch ready for your next investor or partner meeting. You work with a real coach who has mentored founders across Asia since 2016, and every detail is published for you to check at your own pace. Admission is by application. No outcome is guaranteed.
What was reported
Business Standard and ETHealthworld report that the round included Liberty Ridge Capital, a Singapore-based healthcare growth-equity firm, alongside HDFC Bank, Equentis, NAFA Capital Advisors, existing investors 1Crowd and 3i Partners, and several angel investors. Founder and CEO Prabhat Shrivastava said, per ETHealthworld: "This fundraise marks an important milestone in VitusCare's journey. We are focused on building a sustainable dialysis care model that combines clinical excellence with operational efficiency… As we expand our network, we remain focused on maintaining consistent care standards while making quality dialysis services more accessible across underserved markets."
Vasavi Vittal, founder and managing director of Liberty Ridge Capital, told Business Standard: "VitusCare's capital-light model offers a differentiated approach to delivering specialised dialysis care through existing hospital infrastructure. Its growth in network reach, revenue and centre-level performance demonstrates the strength of its operating model."
The numbers, as reported
These figures are company-stated and reported by the outlets. We have not audited them:
- Network grew from 22 to over 60 dialysis centres across nine states and over 50 cities.
- More than 35,000 patients treated and over 8 lakh (800,000+) dialysis sessions delivered.
- Workforce grew from 110 to 300 employees.
- Revenue roughly tripled since the late-2024 round: about ₹44 crore in FY26, with about ₹65 crore targeted for FY27 (Business Standard).
- Positive corporate EBITDA in FY26, with same-centre growth of over 30% (Entrackr).
- A target of more than 100 centres by end-FY27, and exploration of select Asian markets.
One caveat: VitusCare's own website counters are older than the figures reported on 19 November, so treat the site's numbers as outdated, not as the latest word.
The model: dialysis inside existing hospitals
VitusCare, founded in 2017, runs a capital-light "shop-in-shop" model: it places specialised dialysis services inside existing hospitals instead of building standalone clinics. Per Entrackr, the provider brings equipment, trained professionals, technology and operational support, while the hospital supplies the infrastructure. That lowers capital spending and speeds expansion, especially in Tier II and III cities. Its previous round was a ₹22 crore (US$2.7 million) Series A led by Tomorrow Capital in 2024. Proceeds are earmarked for network expansion, technology development, workforce training, AI-native business modules and a Technician Academy, and, per Entrackr, international expansion.
Related News
- Results-focused next step: see the Presentation Skills Coaching Program. The class formats, steps and application process are published on the page, so you can check them yourself, talk with a real coach, and get your pitch ready for your next meeting. No outcome is guaranteed.
- What Are Communication Classes Near Me and What Will You Actually Learn?
- Where Can I Find Public Speaking Coaching Near Me?
Who else is in this space
Entrackr names NephroPlus, Apex Kidney Care, DCDC Kidney Care, 7Med and Rahi Care as comparable Indian dialysis and kidney-care providers. It also gives two dated datapoints: DCDC Kidney Care raised ₹150 crore from Temasek-backed ABC Impact in March 2025, and The Renal Project secured US$1.3 million in a pre-seed round led by JITO Angel Network in September 2026. These companies differ in stage, model and scale, and we did not compare pricing or clinical outcomes. Read this as a map of the segment, not a ranking.
Three presentation lessons from this round
1. Explain the model in three versions. "Capital-light shop-in-shop" is compact for investors but may be opaque to a hospital administrator or a new technician. Prepare one explanation for investors (why each new centre needs less capital), one for hospital partners (what you bring into their building and what stays theirs), and one for employees (what training and career path the model creates; a Technician Academy is that kind of message). Same facts, three frames.
2. Show growth as before-and-after pairs. "22 to 60+ centres", "110 to 300 staff" and "₹44 crore to a ₹65 crore target" show direction and speed better than a single number. Put one number on each slide, state the period, state the source ("company-reported"), and label targets as targets, never blended with results. That is how a metrics story holds up in tough Q&A.
3. Follow up calmly when investors go quiet. Raising a round usually means talking to many prospects, and some will not reply. If that happens to you, one clear follow-up works better than many: restate the single number that changed since their last look, offer a specific next step, and set your own date to move on. Silence can mean timing, budget or fit; it is not automatically a verdict on you. This is general practice, not a claim about anyone in this round.
Ad: our own product. DreamakerAI is described on its page as an all-in-one AI CRM and business operating system. If you want an opportunity to keep your investor and partner follow-ups in one place, the page lists the included tools so you can go through the features step by step, see what it aims to replace, and read the details yourself. It is meant for founders and teams who want to keep their promises to the people they meet. Plans and pricing are on the page; check current details. No results are guaranteed.
The Rare Singapore-to-India Opportunity: What This Round Signals for China and Asia Startups
According to the Chapman University Survey of American Fears, Wave 11 (2025), conducted by SSRS with 1,015 US adults and a margin of error of ±3.6%, 33.7% of respondents said they were afraid or very afraid of public speaking, ranking it #46 of 67 fears. This is a self-reported US measure, not an Asia statistic. We use it only to show that nervousness about speaking is common, and that speaking is a skill people can practise.
Now the analysis, which is our reading and not reported fact. The documented facts are a Singapore-based healthcare growth fund backing an Indian scale-up that, per the outlets, is exploring select Asian markets. One round does not prove a trend, but it points to a window: cross-border capital in Asia pays attention to models it can understand quickly. For founders in Singapore, India and across the region, the opportunity is to have your model, your numbers and your follow-up plan ready before the meeting is booked. No China-specific evidence appears in this round, so for China-based founders this is a conditional lesson only: the same discipline of a model explained for different audiences, sourced metrics and calm follow-up applies if you pitch cross-border investors. Nothing here guarantees funding. Stronger presentation and speaking can help your real numbers be understood, and that is all it can do.
Turn a nervous pitch into a clear one. Apply to Jason Lim's Presentation Skills Coaching Program. The page sets out the formats and steps, so you know what you are signing up for. The aim is a pitch you can deliver with a clear result in mind for your next investor or partner conversation. You get coaching from a real person who has worked with founders in Singapore, Malaysia, China, Taiwan and Indonesia, and all details are published for you to review before you apply. Admission is by application. No outcome is guaranteed.
Sources
- Business Standard: Healthcare startup VitusCare secures ₹30 crore in a Series B funding round (19 Nov 2026)
- ETHealthworld: VitusCare raises $3 million in Series B funding (19 Nov 2026)
- Entrackr: Dialysis care provider VitusCare raises $3 Mn in Series B round (19 Nov 2026)
- Inc42: Prabhat Shrivastava, Founder & CEO, VitusCare (profile)
- VitusCare: company website
- Liberty Ridge Capital: company website
- Chapman University: Survey of American Fears 2025, Key Findings (Wave 11, PDF)
